We found that the expression level of IGF2BP3 increased with tumour grade, and patients with high expression had a worse prognosis than those with low expression in The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) datasets (Fig. S5A- D). This evidence concerns the gene IGF2BP3 and central nervous system cancer.